Compare Marathon Petroleum Corp (MPC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Novartis AG — how do they compare? Marathon Petroleum Corp trades at $401.71 (market cap $111.70B), while Novartis AG trades at $139.66 (market cap $262.64B). The key difference: Novartis AG is far larger — about 2.4× Marathon Petroleum Corp's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| MPC | NVS | |
|---|---|---|
Market Cap | $111.70B | $262.64B |
Sector | Energy | Health |
52-Week High | $399.44 | $168.62 |
52-Week Low | $162.63 | $121.80 |
Enterprise Value | $138.23B | $303.97B |
Dividend Yield | 1.01% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today and near its 52-week high, with a bullish technical outlook from moving averages and strong momentum. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $17.73 surpassing the $14.27 forecast. Valuation ratios appear attractive with a P/E of 13.79 and P/S of 0.77, while profitability metrics like a 47.9% ROE highlight efficient capital use. Recent news emphasizes refinery investments and benefits from geopolitical energy risks.
The outlook for MPC is positive, driven by robust earnings performance, favorable refining margins, and strong analyst support with 26 buy ratings. Key opportunities include high-return projects and cash flow growth, with 2026 net income projected at $8.6B. Risks involve exposure to oil price volatility, cyclical demand, and rising debt-to-asset ratios, which increased to 42.59% in 2025. Investors should weigh solid fundamentals against sector-specific headwinds.
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
